Drug Profile
NTM 1633
Alternative Names: NTM-1633; Xoma 3ELatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator XOMA
- Developer National Institute of Allergy and Infectious Diseases
- Class Antitoxins; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Botulinum toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Botulism(In volunteers, In adults) in USA (IV, Infusion)
- 10 Dec 2020 Phase-I development is ongoing in USA (Xoma pipeline, December 2020)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Botulism in USA (IV, Infusion)